BioCentury | Jan 21, 2021
Product Development

Jan. 20 Quick Takes: AZ, Daiichi get Enhertu approvals in gastric, breast cancer; plus EdiGene, Merck, Oxford, BMS and Omeros

Partners AstraZeneca plc (LSE:AZN; NASDAQ:AZN) and Daiichi Sankyo Co. Ltd. (Tokyo:4568) said HER2-targeted antibody-drug conjugate (ADC) Enhertu fam-trastuzumab deruxtecan-nxki received two additional approvals this week. On Tuesday, FDA approved an sBLA for Enhertu to treat locally...
BioCentury | Jan 21, 2021
Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

The Phase III miss for Merck KGaA’s bintrafusp alfa in non-small cell lung cancer takes one of the most promising indications for the GSK-partnered program out of contention, and raises questions about...
BioCentury | Jan 16, 2021
Product Development

Zymeworks showcases >45% confirmed ORRs for anti-HER2 bispecific in biliary, gastroesophageal cancers

Phase I data Zymeworks presented Friday for its bispecific anti-HER2 mAb back its ongoing and pending pivotal trials in biliary tract and gastroesophageal cancers, respectively. In an oral presentation at the American Society of Clinical Oncology...
BioCentury | Jan 15, 2021
Product Development

Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

Early data showing clinical efficacy of a combination from Arcus in pancreatic cancer increases the likelihood that Gilead will exercise its option on the biotech’s potentially first-in-class molecule targeting CD73. An interim readout from the...
BioCentury | Jan 14, 2021
Finance

With €127M series B, cancer vaccine developer IO Biotech raises second-largest European venture round in the past year

IO Biotech parlayed early clinical data into a €127 million ($154.8 million) series B financing led by HBM Healthcare Investments, which will support a Phase II trial of its leading cancer vaccines in combination with...
BioCentury | Jan 12, 2021
Finance

Diverse syndicate stands behind EQRx’s mission with $500M series B round

EQRx is planning to deliver on its promise to provide equivalent or better low-cost drugs ahead of schedule with a $500 million series B, with diverse investor interest reflecting a mission that has only...
BioCentury | Jan 12, 2021
Deals

Novartis gains rights to BeiGene’s PD-1 in North America, Europe and Japan for $650M up front

After regaining worldwide rights to tislelizumab from Celgene Corp. in mid-2019, BeiGene has found a partner in major-market territories for the PD-1 inhibitor in Novartis, which paid $650 million up front on Monday for rights in...
BioCentury | Jan 12, 2021
Deals

Sanofi joins the myeloid checkpoint movement with Biond deal

Sanofi is staking claims in next-generation checkpoints through a new deal with Israeli biotech Biond around myeloid checkpoint target ILT2.  The deal with Biond Biologics Ltd., which gives the biotech $125 million up front and...
BioCentury | Jan 11, 2021
Deals

Atopic dermatitis readout drives Sanofi’s $1.1B takeout of Kymab

More than a decade after Kymab was first backed by the Wellcome Trust to derive drug candidates from an engineered mouse model, the company has accepted a $1.1 billion takeout offer from Sanofi that closely...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

The pandemic has only deepened the already heavily-weighted oncology focus of many portfolios, and it’s targeted oncology opportunities that are catching the eyes of buysiders in 2021. A combination of...
Items per page:
1 - 10 of 1398